

# BelÃ©n BeltrÃ¡n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5776216/publications.pdf>

Version: 2024-02-01

53  
papers

1,996  
citations

279701

23  
h-index

243529

44  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Oncostatin M, TNF-Î±, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. <i>Digestive Diseases</i> , 2021, 39, 1-9.	0.8	8
2	Recomendaciones del Grupo EspaÃ±ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infecciÃ³n tuberculosa en pacientes con enfermedad inflamatoria intestinal. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2021, 44, 51-66.	0.2	5
3	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. <i>GastroenterologÃ­a Y HepatologÃ­a (English Edition)</i> , 2021, 44, 51-66.	0.0	4
4	Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics. <i>Antioxidants</i> , 2021, 10, 64.	2.2	41
5	Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00416.	1.3	7
6	Recomendaciones del Grupo EspaÃ±ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2020, 43, 649-658.	0.2	7
7	Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease. <i>Digestive Diseases</i> , 2019, 37, 108-115.	0.8	32
8	Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's diseaseâ€”results from the ENEIDA registry. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 600-601.	1.9	0
9	Recomendaciones del Grupo EspaÃ±ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiologÃ­a, diagnÃ³stico y pronÃ³stico. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2019, 42, 568-578.	0.2	11
10	Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 1062.	1.7	8
11	Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. <i>Nutrients</i> , 2019, 11, 1059.	1.7	30
12	Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 459-464.	0.6	17
13	A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1681-1691.	0.9	28
14	Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00083.	1.3	22
15	Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1612-1621.	1.1	6
16	Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease. <i>Digestion</i> , 2019, 100, 27-36.	1.2	3
17	La resonancia magnÃ©tica y el Ã­ndice MaRIA en la valoraciÃ³n preoperatoria de la enfermedad de Crohn ileal. <i>CirugÃ­a EspaÃ±ola</i> , 2019, 97, 582-589.	0.1	3
18	Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-Î± drug failure. <i>Digestive and Liver Disease</i> , 2018, 50, 415-417.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines. <i>Journal of Clinical Apheresis</i> , 2018, 33, 99-103.	0.7	2
20	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 152-157.	0.6	16
21	Vedolizumab, una opción en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biológicos. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 535-543.	0.2	3
22	Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease. <i>Journal of Surgical Research</i> , 2017, 213, 290-297.	0.8	10
23	Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1417-1425.	1.1	12
24	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1454-1460.	0.9	25
25	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. <i>Journal of Gastroenterology</i> , 2017, 52, 788-799.	2.3	50
26	Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs—Current Evidences and Further Aspects to Unravel. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	39
27	Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2016, 26, 641-656.	0.6	14
28	Fecal Calprotectin in Ileal Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1572-1579.	0.9	55
29	Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2515-2532.	0.9	79
30	Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 13999.	1.4	34
31	Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach. <i>Clinical and Translational Gastroenterology</i> , 2013, 4, e36.	1.3	108
32	Assessing an Improved Protocol for Plasma microRNA Extraction. <i>PLoS ONE</i> , 2013, 8, e82753.	1.1	81
33	Impact of Current Smoking on the Clinical Course of Microscopic Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1470-1476.	0.9	54
34	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 411-7.	0.9	80
35	Mo1685 Fecal Calprotectin (FC) is a Useful Early Predictive Marker for Postoperative Recurrence in Crohn's Disease (CD). <i>Gastroenterology</i> , 2012, 142, S-659.	0.6	3
36	Tu1951 Apoptosis Resistance of Crohn's Disease Blood T-Cells Depends on Catalase Activity Inhibition. <i>Gastroenterology</i> , 2012, 142, S-885.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 4391.	1.4	78
38	Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 157-161.	0.6	72
39	Role of oxidative stress and antioxidant enzymes in Crohn's disease. <i>Biochemical Society Transactions</i> , 2011, 39, 1102-1106.	1.6	90
40	Effects of Endotoxin on Neurally-mediated Gastric Acid Secretion in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 1239-1241.	1.2	3
41	Role of the Endothelium in the Relaxation Induced by Propofol and Thiopental in Isolated Arteries from Man. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 430-432.	1.2	19
42	Ulcerative colitis in smokers, non-smokers and ex-smokers. <i>World Journal of Gastroenterology</i> , 2011, 17, 2740.	1.4	102
43	Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 76-86.	0.9	110
44	Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 24-30.	1.0	13
45	Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1387-1391.	0.9	43
46	Response:. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 203-204.	0.5	0
47	Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy?. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 533-540.	0.5	156
48	Videocapsule Endoscopy Versus Colonoscopy for the Diagnosis of Postsurgical Recurrence in Crohn's Disease (CD): A Pilot Study. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB159.	0.5	1
49	Inhibition of mitochondrial respiration by endogenous nitric oxide: A critical step in Fas signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8892-8897.	3.3	122
50	Continuous exposure to high concentrations of nitric oxide leads to persistent inhibition of oxygen consumption by J774 cells as well as extraction of oxygen by the extracellular medium. <i>Biochemical Journal</i> , 2000, 346, 407.	1.7	15
51	Continuous exposure to high concentrations of nitric oxide leads to persistent inhibition of oxygen consumption by J774 cells as well as extraction of oxygen by the extracellular medium. <i>Biochemical Journal</i> , 2000, 346, 407-412.	1.7	35
52	Oxidative stress and S-nitrosylation of proteins in cells. <i>British Journal of Pharmacology</i> , 2000, 129, 953-960.	2.7	186
53	Synthesis of nitric oxide in the dorsal motor nucleus of the vagus mediates the inhibition of gastric acid secretion by central bombesin. <i>British Journal of Pharmacology</i> , 1999, 127, 1603-1610.	2.7	21